Showing: 1 - 3 of 101 RESULTS
Banner News Niemann-Pick Type C News Research News

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million related to NPC drug approval

February 27, 2025 at 7:31 AM EST CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease …